ITP
AMLX icon

Iron Triangle Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Iron Triangle Partners’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-240,240
Closed -$8.88M – 28
2022
Q4 		$8.88M Buy
+240,240
New +$8.53M 1.59% 22

Other funds holding AMLX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Iron Triangle Partners's AMLX Position: Q1 2023 in Review

Iron Triangle Partners sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2023, closing a stake of 240,240 shares — an estimated $8.88M sold.

Iron Triangle Partners first reported a position in AMLX in Q4 2022 and held it in 1 quarter. The position peaked at $8.88M in Q4 2022. 147 funds tracked by Wall St. Rank hold AMLX as of Q1 2023.

  • Iron Triangle Partners reported no remaining Amylyx Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Iron Triangle Partners sold 240,240 Amylyx Pharmaceuticals shares in Q1 2023, an estimated $8.88M.
  • Iron Triangle Partners first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Iron Triangle Partners's Amylyx Pharmaceuticals position peaked at $8.88M in Q4 2022.
  • 147 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2023.

Based on Iron Triangle Partners's 13F filing for Q1 2023, filed 15 May 2023.